1290191-64-8 Usage
Uses
Used in Organic Synthesis:
Tert-butyl N-[(1R,3R)-3-hydroxycyclopentyl]carbamate is utilized as a protecting group for amines, facilitating the selective manipulation of functional groups in complex organic molecules. This selective protection is crucial for the synthesis of intricate organic compounds where precise control over the reaction is necessary.
Used in Pharmaceutical Research and Drug Development:
In the pharmaceutical industry, tert-butyl N-[(1R,3R)-3-hydroxycyclopentyl]carbamate serves as a valuable building block for the synthesis of a variety of biologically active compounds. Its unique structure and reactivity make it a key component in the creation of new drugs with potential therapeutic applications.
tert-butyl N-[(1R,3R)-3-hydroxycyclopentyl]carbamate's versatility in both organic synthesis and pharmaceutical development highlights its importance in the field of chemistry, particularly in the design and synthesis of novel molecules with specific biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 1290191-64-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,9,0,1,9 and 1 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1290191-64:
(9*1)+(8*2)+(7*9)+(6*0)+(5*1)+(4*9)+(3*1)+(2*6)+(1*4)=148
148 % 10 = 8
So 1290191-64-8 is a valid CAS Registry Number.
1290191-64-8Relevant academic research and scientific papers
Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
-
Paragraph 0176, (2017/04/04)
The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
